NCT03550508 (JMT103) is a Phase 1 clinical trial of Anti-RANKL Monoclonal Antibody in Bone Metastases, sponsored by Shanghai JMT-Bio Inc..

Who is sponsoring NCT03550508?

NCT03550508 is sponsored by Shanghai JMT-Bio Inc..

What drugs are being tested in NCT03550508?

Interventions in NCT03550508: Anti-RANKL Monoclonal Antibody.

What condition does NCT03550508 study?

NCT03550508 studies Bone Metastases.

Is NCT03550508 still recruiting?

NCT03550508 is currently status unknown. Last updated 8 June 2018.

Last reviewed 2018-06-08 · How we verify

NCT03550508: JMT103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors

Status unknown Phase 1 Last updated 8 June 2018

What this trial tests

Phase 1 trial testing Anti-RANKL Monoclonal Antibody in Bone Metastases in 36 participants. Status unknown.

Timeline

21 May 2018

Primary endpoint
30 August 2019

1 December 2019

Quick facts

Lead sponsor	Shanghai JMT-Bio Inc.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	21 May 2018
Primary completion	30 August 2019
Estimated completion	1 December 2019
Sites	1 location across China

Drugs / interventions tested

Anti-RANKL Monoclonal Antibody — full drug profile →

Conditions studied

Bone Metastases — all drugs for Bone Metastases →

Sponsor

Shanghai JMT-Bio Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Bone Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

JMT103 is a novel, full human IgG4 monoclonal antibody targeting RANKL. In preclinical studies, JMT103 demonstrated strong activity through blocking RANKL receptor, RANK on the surface of osteoclasts, leading to inhibit osteoclast differentiation, activation, and maturation and reduce bone resorption. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) ,to evaluate the safety, pharmacokinetics and preliminary efficacy (bone turnover markers) of recombinant fully human Anti-RANKL Monoclonal Antibody (JMT103) in patients with bone metastases from tumors at single doses and multiple doses. About 36 cases patients are to be recruited.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2023.
Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, et al · · 2023 · cited 204× · PMID 36472472 · DOI 10.1080/19420862.2022.2153410
Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu.
Colombo M, Mirandola L, Chiriva-Internati M, Basile A, et al · · 2018 · cited 51× · PMID 30154786 · DOI 10.3389/fimmu.2018.01823
Chemokines network in bone metastasis: Vital regulators of seeding and soiling.
Sharma G, Pothuraju R, Kanchan RK, Batra SK, et al · · 2022 · cited 14× · PMID 35124194 · DOI 10.1016/j.semcancer.2022.02.003
Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors.
Liang X, Xue J, Ge X, Li J, et al · · 2022 · cited 8× · PMID 35992822 · DOI 10.3389/fonc.2022.971594

Verify or expand the search:

Other recruiting trials for Bone Metastases

Currently open trials in the same condition.

NCT06713941 — Management of Bone Metastases · active not recruiting
NCT06392217 — clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases · recruiting
NCT06065449 — A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation T · Phase 3 · recruiting
NCT06487013 — Effectiveness and Safety of ArcBlate Palliative Treatment for Patients With Painful Bone Metastases: A Pivotal Study · NA · recruiting
NCT06189079 — Arterial Embolization for the Treatment of Bone Metastases: Prospective Observational Study · recruiting

Other Shanghai JMT-Bio Inc. trials

Trials by the same sponsor.

NCT07441460 — A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · Phase 3 · recruiting
NCT07472647 — SYS6090 Combination Therapy in Advanced Lung Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07384377 — JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed · Phase 3 · not yet recruiting
NCT07419698 — Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants · Phase 1 · recruiting
NCT07332533 — A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03550508 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai JMT-Bio Inc.
Last refreshed: 8 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03550508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing